<DOC>
	<DOCNO>NCT02607215</DOCNO>
	<brief_summary>Platinum Retreated Patients Platinum Sensitive mTNBC</brief_summary>
	<brief_title>Platinum Rechallenge Patients With Platinum-sensitive mTNBC</brief_title>
	<detailed_description>Platinum Retreated Second- Third-line Patients Platinum Sensitive Metastatic Triple Negative Breast Cancer ( randomise , phase II , NPN trial )</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>1 . Females age 18 70 year old 2 . Performance status 2 3 . Life expectancy longer 3 month 4 . Histological proven unresectable recurrent advance breast cancer 5 . Triplenegative estrogen receptor ( ER ) , progestogen receptor ( PR ) , human epithelial receptor2 ( HER2 ) immunohistochemistry ( ER &lt; 1 % , PR &lt; 1 % Her2 negative ) . A negative Her2 gene amplification verify FISH test patient Her2 ( 2+ ) . 6 . Patients must progress 1or 2 prior chemotherapy regimens metastatic disease , cis/carboplatin pretreated 1 previous line prior randomisation . Platinum sensitive study define complete partial stable disease follow completion ( minimum 4 treatment cycle ) previous platinumbased chemotherapy disease progression great 3 month completion last dose platinum chemotherapy ( last dose ) . 7 . At least one measurable disease accord response evaluation criterion solid tumor ( RECIST 1.1 ) 8 . Radiation therapy within 4 week prior enrollment 9 . All patient enrol required adequate hematologic , hepatic , renal function 10 . Be able understand study procedure sign inform consent . 1 . Patients prior treatment vinorelbine 2 . Pregnant lactate woman , woman childbearing potential , unwilling use adequate contraceptive protection process study 3 . Patients symptomatic central nervous system metastasis permit , except stable asymptomatic brain metastasis complete cranial irradiation , least one measurable lesion outside brain . Radiotherapy complete within 4 week prior registration 4 . Treatment investigational product within 4 week first treatment 5 . Severe cardiopulmonary insufficiency , severe hepatic renal dysfunction 6 . Uncontrolled serious infection 7 . Other active malignancy ( include hematologic malignancy ) malignancy , except cure nonmelanoma skin cancer cervical intraepithelial neoplasia .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>